Sanofi
Biosimilar developer, France. 3 development products across 3 molecules: insulin aspart, insulin human, insulin lispro.
First approval in the Atlas: Nov 2013, Shantha Biotechnics (INN only), insulin human (CDSCO)
FDAproducts approved1
EMAproducts approved2
PMDAproducts approved2
HCproducts approved2
CDSCOproducts approved2
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Insulin aspart | Merilog / Insulin aspart Sanofi SAR341402 | Feb 2025 | Jun 2020 | Mar 2021 | Oct 2020 | May 2023 | · |
| Insulin human | Shantha human insulin | · | · | · | · | Nov 2013 | · |
| Insulin lispro | Insulin lispro Sanofi SAR342434 | · | Jul 2017 | Mar 2020 | Nov 2017 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCONov 2013Shantha Biotechnics (INN only), insulin human
- EMAJul 2017Insulin lispro Sanofi, insulin lispro
- HCNov 2017Admelog, insulin lispro
- PMDAMar 2020Insulin Lispro BS HU Sanofi, insulin lispro
- EMAJun 2020Insulin aspart Sanofi, insulin aspart
- HCOct 2020Trurapi, insulin aspart
- PMDAMar 2021Insulin Aspart BS NR Sanofi, insulin aspart
- CDSCOMay 2023Sanofi India (INN only), insulin aspart
- FDAFeb 2025Merilog, insulin aspart
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.